RNAi Technology Market by Application and Geography - Forecast and Analysis 2020-2024

The global RNAi technology market size has the potential to grow by USD 1.96 billion during 2020-2024. The market’s growth momentum will accelerate throughout the forecast period.

This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW) and application (cancer, infectious diseases, ophthalmic diseases, genetic diseases, and other diseases). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Dicerna Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Merck KGaA, QIAGEN NV, and Thermo Fisher Scientific Inc.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of RNAi technology market

Request a FREE sample now!

Market Competitive Analysis

The RNAi technology market is currently fragmented. The degree of fragmentation will remain the same over the forecast period. The rising commercial approvals of RNAi therapy and increasing R&D in RNAi therapeutics are providing market vendors with significant growth opportunities. Horizon Discovery Group Plc, Merck KGaA, QIAGEN NV, and Thermo Fisher Scientific Inc. are a few of the substantial market participants.

Although the accelerating market growth momentum will offer immense business opportunities to vendors, a long approval process and stringent regulations will challenge the growth of many. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market positions, this RNAi technology market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of the companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. This RNAi technology market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of their future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading RNAi technology companies, including:

• Alnylam Pharmaceuticals Inc.
• Arbutus Biopharma Corp.
• Arrowhead Pharmaceuticals Inc.
• Bio-Rad Laboratories Inc.
• Dicerna Pharmaceuticals Inc. 
• F. Hoffmann-La Roche Ltd.
• Horizon Discovery Group Plc
• Merck KGaA
• QIAGEN NV
• Thermo Fisher Scientific Inc.   

RNAi Technology Market: Segmentation by Region

For more insights on the RNAi technology market share of various regions Request for a FREE sample now!

North America accounted for the largest market share in 2019. The growth in drug development and research and approval of RNAi therapeutics by regulatory authorities such as the US FDA are fueling the RNAi technology market growth in North America.

Almost 59% of the overall market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for RNAi technology in the region. The market growth rate in this region will be slower than that of Asia and ROW over the forecast period.

RNAi Technology Market: Segmentation by Application

Request for a FREE sample and Get more information on the market contribution from various diagnostic methods segments

RNAi is finding considerable adoption in cancer treatments owing to its targeted treatment ability. RNAi technology can identify and target undruggable carcinogenic molecules. As a result, the use of technology is increasing in treating cancer. Furthermore, vendors are focusing on developing RNAi-based targeted cancer therapies using advanced lipid and polymer-based nanocarriers as a delivery platform. The rising prevalence of cancer is increasing the demand for RNAi technology. As a result, the RNAi technology market growth by the cancer segment will be significant over the forecast period.

The growth rate of the cancer segment is expected to be faster compared with the infectious diseases and ophthalmic diseases segment over the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the RNAi technology market size.

RNAi Technology Market: Key Drivers and Trends

RNAi therapeutics deals with the use of the natural RNAi pathway to silence the disease-causing genes and knock down the production of the protein that expresses the condition. The technology is primarily used in the field of oncology. Many vital targets in cancer treatments have been proven undruggable. Therefore, siRNA is used to target the mRNA and not oncogene protein in cancer treatments, making the undruggable target accessible for small siRNA during cancer treatments. Leveraging the significant application of RNAi technology, therapeutic manufacturers are significantly focusing on the development of RNAi-based targeted cancer therapies, which are primarily advanced lipid and polymer-based nanocarriers. As the RNAi technology has made every gene in the human genome a druggable target, the demand for the technology as therapeutics is rising. As a result, the RNAi technology market growth over the forecast period is expected to be substantial over the forecast period.

• RNAi screening is offering significant growth opportunities in the genome-scale high-throughput analysis (whole-genome screening) of gene functions.
• The adoption of RNAi high-throughput screening in the development of RNAi therapeutic technology, identification of therapeutic targets, gene regulation in cell biological processes, identification of novel signaling pathway, and cancer gene screening is promoting developments in the RNAi technology.
• Advances in RNAi screening, which is one of the key RNAi technology market trends, are offering a potential for the rapid identification of highly specific tumor-targeting ligands.
• In vivo high-throughput screening of large peptide libraries or aptamers is one of the advanced RNAi screening procedures.
• In vitro RNAi screening, using cell lines with distinct mutational features has helped in the identification of key cancer targets.
• The RNAi technology market will grow at a CAGR of over 22% during 2020-2024.

Request for a FREE sample now!

RNAi Technology Market: Key Highlights of the Report for the Forecast Period 2020-2024

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will accelerate the growth of the RNAi technology market during the next five years
• Precise estimation of the global RNAi technology market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the RNAi technology industry in Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of RNAi technology vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch